Information Provided By: 
Fly News Breaks for August 7, 2018
NBIX
Aug 7, 2018 | 08:00 EDT
Stifel analyst Paul Matteis initiated coverage of Neurocrine Biosciences with a Buy rating and $137 price target and added the stock to the firm's Select List. He sees Ingrezza in Tardive Dyskineisa having "blockbuster potential" and believes the drug has "a reasonable shot at succeeding" and expanding its market in Tourette's Syndrome. He also estimates cash flows from Elagolix could be worth close to $2B, Matteis tells investors.
News For NBIX From the Last 2 Days
